ANCA associated vasculitis
Clinical trials for ANCA associated vasculitis explained in plain language.
Never miss a new study
Get alerted when new ANCA associated vasculitis trials appear
Sign up with your email to follow new studies for ANCA associated vasculitis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cheaper rituximab versions just as safe and effective for rare vasculitis?
Disease control CompletedThis study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
Disease control CompletedThis study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
COVID-19's hidden toll on autoimmune patients revealed
Knowledge-focused CompletedThis study followed 293 people with autoimmune diseases and healthy volunteers to see how COVID-19 infection or vaccination affects their immune system, inflammation, and blood vessels. Participants were grouped based on their COVID-19 history and had up to 5 visits over 12-18 mo…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a vaccine test expose hidden immune weakness?
Knowledge-focused CompletedThis trial tests whether rituximab, a drug used for ANCA-associated vasculitis, leaves patients with a weakened immune system. Researchers give pneumococcal vaccines to patients treated with rituximab, patients with the disease but not on rituximab, and healthy volunteers. They c…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase 2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
A blood clue to a rare vessel disease?
Knowledge-focused CompletedThis study looks at whether a protein in the blood, called soluble CD95 ligand, plays a role in ANCA-associated vasculitis, a rare group of diseases that cause inflammation of blood vessels. Researchers will collect blood and urine samples from 48 adults with the condition and tr…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood filter showdown: which method clears harmful antibodies faster?
Knowledge-focused CompletedThis study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help do…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC